相关实验视频

Updated: Jun 26, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

新兴药物概况:JAK抑制剂

Alexander Coltoff¹, Andrew Kuykendall²

¹Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.

Leukemia & lymphoma

|May 13, 2024

概括

简氏激酶 (JAK) 抑制剂有助于骨髓纤维化患者,但耐药性限制了有效性. 将JAK抑制剂与其他疗法结合起来,有望在治疗这种骨髓疾病时获得更好,更长的反应.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

失调的Janus激酶/信号转换器和转录激活器 (JAK/STAT) 信号传输是髓纤维化病原发生的关键驱动因素.
雅克抑制剂是第一线治疗的基石,在骨髓纤维化患者的胀,症状和细胞衰竭方面具有好处.

研究的目的:

审查JAK/STAT信号在骨髓纤维化中的作用.
探索潜在的协同治疗标和最近在涉及JAK抑制剂用于骨髓纤维化治疗的JAK抑制剂组合策略的进展.

主要方法:

关于骨髓纤维化中JAK/STAT信号的当前文献的综述.
对新型组合疗法的最新III期临床试验数据的分析.
讨论针对 JAK 抑制的辅助路径的生物学理由.

主要成果:

单剂JAK抑制提供了临床益处,但由于耐药性机制的变化或短暂反应,往往受到限制.
新兴的组合策略涉及新型药物添加到JAK抑制剂,在最近的III期试验中满足了主要终点.
目前正在进行的后期研究正在调查骨髓纤维化结合疗法的进一步进展.

结论:

通过联合治疗克服JAK抑制剂耐药性对于改善骨髓纤维化患者的治疗结果至关重要.
针对与JAK抑制剂协同合作的信号通路提供了一个有希望的策略,以提高响应率和耐用性.
未来的研究和临床试验将继续完善用于骨髓纤维化管理的组合方法.

关键词:

阻碍了JAK的发生.多国民族国家 (MPNs) 是一个多国民族国家.骨髓纤维化骨髓纤维化卢克索利提尼布 (Ruxolitinib) 是一种药物.

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...